Prediction of Preeclampsia in Nulliparous Women According to First Trimester Maternal Factors and Serum Markers
Overview
Affiliations
Objective: To evaluate the performance of maternal risk factors (BMI and mean arterial pressure [MAP]) and first-trimester maternal serum markers in the early prediction of preeclampsia (PE) in nulliparous women.
Material And Methods: This was a case-cohort study based on a cohort of 14,207 nulliparous women. A total of 213 cases with term PE (from 37 weeks + 0 days) and 55 cases with preterm PE (before 37 weeks + 0 days) were identified and validated. Randomly, 449 controls were selected. Serum samples previously collected for the double test (pregnancy-associated plasma protein A [PAPP-A] and free β human chorionic gonadotrophin [hCGβ]) as part of the first-trimester screening program were retrieved and analyzed for placental growth factor (PlGF), soluble fms-like tyrosine kinase 1 (sFlt-1), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and neutrophil gelatinase-associated lipocalin (NGAL). Concentrations were transformed to multiples of the median (MoM). Multivariate regression analysis was used for prediction models. Receiver-operating characteristics (ROC) curves were used for evaluation of the screening performance.
Results: In preterm PE, the PlGF (0.79 MoM), sFlt-1 (0.86 MoM), NGAL (1.15 MoM), and PAPP-A (0.89 MoM) medians were significantly altered. In term PE, PlGF (0.90 MoM) and NT-proBNP (0.86 MoM) medians were significantly reduced. The combination of MAP and PlGF yielded a 39% detection rate of preterm PE for a 10% false-positive rate. The combination of MAP, BMI, and PlGF yielded a 33% detection rate of term PE with a 10% false-positive rate.
Conclusion: First-trimester MAP, maternal serum PlGF, and NGAL are markers of preterm PE. Maternal serum sFlt-1 is a significant marker of preterm PE, but only early in the first trimester. First-trimester maternal serum NT-proBNP is not a predictor of PE. Screening performance for PE with these markers individually or in combination is modest.
Cowan S, Lang S, Goldstein R, Enticott J, Taylor F, Teede H Healthcare (Basel). 2024; 12(13).
PMID: 38998895 PMC: 11241067. DOI: 10.3390/healthcare12131361.
Tiruneh S, Vu T, Rolnik D, Teede H, Enticott J Curr Hypertens Rep. 2024; 26(7):309-323.
PMID: 38806766 PMC: 11199280. DOI: 10.1007/s11906-024-01297-1.
Takahashi M, Suzuki L, Takahashi N, Hanaue M, Soda M, Miki T Sci Rep. 2024; 14(1):12225.
PMID: 38806648 PMC: 11133404. DOI: 10.1038/s41598-024-63206-5.
Callbo P, Junus K, Gabrysch K, Bergman L, Poromaa I, Lager S Reprod Sci. 2024; 31(5):1391-1400.
PMID: 38253981 PMC: 11090924. DOI: 10.1007/s43032-023-01445-z.
Schuermans A, Truong B, Ardissino M, Bhukar R, Slob E, Nakao T JAMA Cardiol. 2024; 9(3):209-220.
PMID: 38170504 PMC: 10765315. DOI: 10.1001/jamacardio.2023.4994.